Clearside Biomedical Approves Share Increase at Annual Meeting

Clearside Biomedical ( (CLSD) ) just unveiled an update.

On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Spark’s Take on CLSD Stock

According to Spark, TipRanks’ AI Analyst, CLSD is a Neutral.

Clearside Biomedical’s overall stock score is primarily impacted by its weak financial performance and valuation concerns. While there are positive developments in clinical trials and partnerships, the financial instability and requirement for additional funding weigh heavily on the score. Technical analysis also suggests a lack of strong momentum, contributing to the low score.

To see Spark’s full report on CLSD stock, click here.

More about Clearside Biomedical

Average Trading Volume: 177,044

Technical Sentiment Signal: Sell

Current Market Cap: $60.61M

See more data about CLSD stock on TipRanks’ Stock Analysis page.